Gleneagles Hong Kong co-organised a thematic session titled “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” at the ASGH, bringing together leaders from healthcare, academia and the technology sector to discuss the deployment of AI at scale to transform the healthcare industry.

(12 May 2026 – Hong Kong) Gleneagles Hong Kong (“Gleneagles”), part of the IHH Healthcare multinational network, has been taking a leading role at the Asia Summit on Global Health (“ASGH”) jointly organised by the HKSAR Government and the Hong Kong Trade Development Council. Since the Summit’s inception, Gleneagles has been the Future Private Health Partner for the past five consecutive years and is a Thematic Session Partner in 2026.

Held under the theme of “Fuelling Healthcare Breakthroughs”, this year’s ASGH convenes global policymakers, healthcare leaders, investors and innovators to advance collaboration and drive the future of healthcare. Drawing on IHH’s global expertise, scale and partnerships, Gleneagles leverages its strengths to address the evolving local and regional health needs, translating innovation into real-world clinical impact.

Gleneagles’ participation at ASGH reflects IHH’s Care. For Good. sustainability aspiration to deliver clinical excellence and enhance patient care across the continuum. It also underscores Gleneagles’ continued commitment to strengthening Hong Kong’s position as an international health and medical innovation hub, while accelerating the adoption of transformative technologies across the region.

At this year’s Summit, Gleneagles led a thematic session titled “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution”, bringing together leaders from healthcare, academia and the technology sector to discuss the deployment of AI at scale to transform the healthcare industry and deliver tangible clinical and operational impact.

Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, said, “At IHH, everything we do is anchored in our Care. For Good. aspiration. We are committed to delivering high-quality care that is both sustainable and accessible to all patients. AI has proven to be a key enabler in enhancing the end-to-end patient journey, helping to elevate clinical outcomes and the overall patient experience.

Our focus is now on impactful adoption – that is, translating innovation into real clinical use that allows us to scale solutions with measurable outcomes. Beyond co-developing AI solutions, we are working with our partners to ensure equal levels of practical applicability, in order for AI-empowered technology to become truly trustworthy and transformative tools for both clinicians and patients in real-world healthcare settings.”

The session featured a distinguished panel of experts from across healthcare, academia and technology, including Professor Joshua Ho, Assistant Dean (Innovation & Technology Transfer) at the Li Ka Shing Faculty of Medicine, The University of Hong Kong; Professor Kwang Joon Kim, Co-founder and Chief Executive Officer at AITRICS; Mr Kwok Quek Sin, Group Chief Business Technology Officer at IHH Healthcare; and Professor Aurel Kun Qian, Co-founder & Chief Medical Officer at SenseCare (healthcare arm of SenseTime).

The discussion highlighted several key priorities accelerating AI adoption in healthcare at scale:

• Bridging R&D and adaptation: harnessing today’s proliferation of data to enable the application of innovation into clinically validated medical solutions backed by research
• Strong data foundation: strengthening interoperable, high-quality and secure data foundations to support trusted AI adoption
• Trust as an accelerator: robust data governance and risk assessment build user confidence, enabling faster and more efficient AI deployment
• Demonstrating clinical and economic value: applying value-based frameworks to ensure AI solutions deliver measurable outcomes while addressing cost pressures in healthcare systems

IHH Healthcare has established Hong Kong as a strategic hub for advancing healthcare innovation, including the development of an AI Lab in 2025. The Lab facilitates collaboration between clinicians, academia and startups to develop and scale AI-enabled solutions in real-world clinical settings, which can potentially be implemented across IHH’s network to deliver meaningful benefits to patients in different regions.

Through its participation at ASGH 2026, Gleneagles continues to foster cross-sector collaboration and drive the adoption of innovations that enhance patient outcomes and healthcare system efficiency.